Tenaya Therapeutics (TNYA) Total Non-Current Liabilities (2020 - 2026)

Tenaya Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $28.5 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 17.28% year-over-year to $28.5 million in Q1 2026; TTM through Mar 2026 was $28.5 million, a 17.28% increase from a year earlier, with the FY2025 full-year figure at $23.2 million, down 13.28% from the prior year.
• Total Non-Current Liabilities improved to $28.5 million in Q1 2026 per TNYA's latest filing, from $23.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $35.3 million in Q4 2022 and bottomed at $21.8 million in Q3 2025.
• The 5-year median for Total Non-Current Liabilities is $28.5 million (2026), against an average of $28.1 million.
• Across the five-year window, Total Non-Current Liabilities advanced 28.96% in 2022 and fell 23.83% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $35.3 million in 2022, then decreased by 12.74% to $30.8 million in 2023, then declined by 13.08% to $26.8 million in 2024, then declined by 13.28% to $23.2 million in 2025, then climbed by 22.44% to $28.5 million in 2026.
• Per Business Quant, the three latest TNYA Total Non-Current Liabilities figures stand at $28.5 million (Q1 2026), $23.2 million (Q4 2025), and $21.8 million (Q3 2025).